Tumor Biology

, Volume 35, Issue 10, pp 9987–9992 | Cite as

RETRACTED ARTICLE: Epidermal growth factor induces FoxO1 nuclear exclusion to activate MMP7-mediated metastasis of larynx carcinoma

  • Hao Ding
  • Yi Zhu
  • Tianqing Chu
  • Shengzi Wang
Research Article


The molecular mechanism underlying cancer invasiveness and metastasis of larynx carcinoma remains elusive. Here we reported a strong correlation between phosphorylated epidermal growth factor receptor (EGFR) and matrix metalloproteinase-7 (MMP7) levels in larynx carcinoma patients. To examine whether a causal link exists, we used a human larynx carcinoma line, Hep-2, to study the molecular basis of EGFR signaling and MMP7 activation. We found that EGF-induced EGFR phosphorylation in Hep-2 cells resulted in activation of MMP7 and, consequently, an increase in cancer invasiveness. An EGFR inhibitor efficiently blocked this EGF-induced activation of MMP7. Moreover, an inhibitor for PI3 kinase (PI3K)/Akt, but not an inhibitor for mitogen-activated protein kinase (MAPK) or an inhibitor for c-Jun N-terminal kinase (JNK), significantly inhibited the EGF-induced activation of MMP7, suggesting that PI3K/Akt signaling cascades may be responsible for EGF-activated MMP7. Further dissection of the pathway revealed that nuclear exclusion of Akt downstream target, FoxO1, was induced by EGF-induced Akt activation and could be inhibited by either the EGFR inhibitor or by the PI3K/Akt inhibitor. Expression of a constitutive nuclear form of FoxO1 significantly inhibited MMP7 activation induced by EGF. Taken together, these findings suggest that EGF/EGFR signaling activates downstream PI3K/Akt to induce FoxO1 nuclear exclusion, which activates MMP7 to promote larynx carcinoma metastasis. Thus, Akt and FoxO1 appear to be promising therapeutic targets for preventing the metastasis of larynx carcinoma.


Epidermal growth factor PI3 kinase FoxO1 Larynx carcinoma MMP7 Cancer invasiveness Cancer metastasis 



This work was supported by the Key Project of Shanghai Committee of Science and Technology, China (No. 12JC1402102), the National Natural Science Foundation of China (No. 81302004), and the Comprehensive Prevention and Control Project of Chronic Disease of Shanghai Shenkang Hospital Development Center, China (No. SHDC12012317).

Conflicts of interest

The authors have declared that no competing interests exist.


  1. 1.
    Nadal A, Cardesa A. Molecular biology of laryngeal squamous cell carcinoma. Virchows Arch. 2003;442:1–7.PubMedGoogle Scholar
  2. 2.
    Dufour A, Overall CM. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol Sci. 2013;34:233–42.CrossRefPubMedGoogle Scholar
  3. 3.
    Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood). 2006;231:20–7.Google Scholar
  4. 4.
    Burke B. The role of matrix metalloproteinase 7 in innate immunity. Immunobiology. 2004;209:51–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Wielockx B, Libert C, Wilson C. Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation? Cytokine Growth Factor Rev. 2004;15:111–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Li Z, Zhang D, Zhang H, Miao Z, Tang Y, Sun G, et al. Prediction of peritoneal recurrence by the mRNA level of CEA and MMP-7 in peritoneal lavage of gastric cancer patients. Tumour Biol. 2014;35:3463–70.CrossRefPubMedGoogle Scholar
  7. 7.
    Koskensalo S, Louhimo J, Nordling S, Hagstrom J, Haglund C. MMP-7 as a prognostic marker in colorectal cancer. Tumour Biol. 2011;32:259–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Koskensalo S, Mrena J, Wiksten JP, Nordling S, Kokkola A, Hagstrom J, et al. MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 2010;31:149–55.CrossRefPubMedGoogle Scholar
  9. 9.
    Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, Wang Y, Yan Y, et al. The matrix metalloprotease pump-1 (MMP-7, matrilysin): a candidate marker/target for ovarian cancer detection and treatment. Tumour Biol. 1999;20:88–98.CrossRefPubMedGoogle Scholar
  10. 10.
    Kim S, Choi JH, Lim HI, Lee SK, Kim WW, Cho S, et al. EGF-induced MMP-9 expression is mediated by the JAK3/Erk pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cell Signal. 2009;21:892–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol. 2009;218:460–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Hirsch FR, Janne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, et al. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol. 2013;8:373–84.CrossRefPubMedGoogle Scholar
  13. 13.
    Kobayashi K, Hagiwara K. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol. 2013;8:27–33.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Sasaki T, Hiroki K, Yamashita Y. The role of epidermal growth factor receptor in cancer metastasis and microenvironment. BioMed Res Int. 2013;2013:546318.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Monsalve M, Olmos Y. The complex biology of FOXO. Curr Drug Targets. 2011;12:1322–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Biggs 3rd WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A. 1999;96:7421–6.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Radiation Oncology, Eye & ENT HospitalFudan UniversityShanghaiChina
  2. 2.Department of Pulmonary Medicine, Shanghai Chest HospitalShanghai Jiaotong UniversityShanghaiChina

Personalised recommendations